Incyte | INCY - Pre Tax Profit

Stock Price
97.80
Daily Change
2.08 2.17%
Monthly
8.27%
Yearly
61.84%
Q2 Forecast
92.62

Incyte reported $389.94M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 26.32M 18.28M Dec/2025
Agenus USD -10.61M 263.52M Dec/2025
Agios Pharmaceuticals USD -109.06M 5.62M Dec/2025
Alnylam Pharmaceuticals USD 161.14M 77.83M Dec/2025
Amgen USD 3.92B 2.35B Sep/2025
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Biogen USD 557.3M 186.7M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Eli Lilly USD 7.23B 456M Sep/2025
Exelixis USD 252.69M 275K Dec/2025
Gilead Sciences USD 2.08B 1.56B Dec/2025
Incyte USD 389.94M 92.37M Dec/2025
Ionis Pharmaceuticals USD -228M 99M Dec/2025
MacroGenics USD -14.93M 31.75M Dec/2025
Merck USD 6.74B 22M Sep/2025
Moderna USD -187M 631M Sep/2025
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Neurocrine Biosciences USD 239.4M 52.4M Dec/2025
Novartis USD 4.64B 445M Dec/2025
Novartis USD 5.17B 637M Sep/2025
Pfizer USD 3.33B 290M Sep/2025
PTC Therapeutics USD -139.08M 116.01M Dec/2025
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Sarepta Therapeutics USD -407.67M 213.63M Dec/2025
Ultragenyx Pharmaceutical USD -128M 51.54M Dec/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025